Publication list - Publika - Scientific publications from Oslo University Hospital

Publications by Olav Dalgard

99 publications found

Original articles

Druckrey-Fiskaaen KT, Vold JH, Madebo T, Midgard H, Dalgard O, Leiva RA, Fadnes LT, INTRO-HCV Study Group (2024)
Liver stiffness and associated risk factors among people with a history of injecting drugs: a prospective cohort study
Subst Abuse Treat Prev Policy, 19 (1), 21
DOI 10.1186/s13011-024-00603-z, PubMed 38532435

Midgard H, Malme KB, Pihl CM, Berg-Pedersen RM, Tanum L, Klundby I, Haug A, Tveter I, Bjørnestad R, Olsen IC, Finbråten AK, Dalgard O (2024)
Opportunistic Treatment of Hepatitis C Infection Among Hospitalized People Who Inject Drugs (OPPORTUNI-C): A Stepped Wedge Cluster Randomized Trial
Clin Infect Dis, 78 (3), 582-590
DOI 10.1093/cid/ciad711, PubMed 37992203

Holmberg M, Aass HCD, Dalgard O, Samuelsen E, Sun D, Björkström NK, Johannessen A, Reikvam DH (2023)
Treatment cessation in HBeAg-negative chronic hepatitis B: clinical response is associated with increase in specific proinflammatory cytokines
Sci Rep, 13 (1), 22590
DOI 10.1038/s41598-023-50216-y, PubMed 38114718

Handal N, Whitworth J, Lyngbakken MN, Berdal JE, Dalgard O, Bakken Jørgensen S (2023)
Mortality and length of hospital stay after bloodstream infections caused by ESBL-producing compared to non-ESBL-producing E. coli
Infect Dis (Lond), 56 (1), 19-31
DOI 10.1080/23744235.2023.2261538, PubMed 37795955

Opheim E, Dalgard O, Ulstein K, Sørli H, Backe Ø, Foshaug T, Couëssurel Wüsthoff LE, Midgard H (2023)
Towards elimination of hepatitis C in Oslo: Cross-sectional prevalence studies among people who inject drugs
Int J Drug Policy, 123, 104279
DOI 10.1016/j.drugpo.2023.104279, PubMed 38061225

Malme KB, Ulstein K, Finbråten AK, Wüsthoff LEC, Kielland KB, Hauge J, Dalgard O, Midgard H (2023)
Hepatitis C treatment uptake among people who inject drugs in Oslo, Norway: A registry-based study
Int J Drug Policy, 116, 104044
DOI 10.1016/j.drugpo.2023.104044, PubMed 37149914

Cheng Q, Cunningham EB, Shih S, Amin J, Bruneau J, Artenie AA, Powis J, Litwin AH, Cooper C, Dalgard O, Hellard M, Bruggmann P, Marks P, Lacombe K, Stedman C, Read P, Hajarizadeh B, Dunlop AJ, Conway B, Feld JJ, Dore GJ, Grebely J, SIMPLIFY and D3FEAT Study Groups (2023)
Patient-Reported Outcomes During and After Hepatitis C Virus Direct-Acting Antiviral Treatment Among People Who Inject Drugs
Value Health, 26 (6), 883-892
DOI 10.1016/j.jval.2022.12.016, PubMed 36646278

Trøseid M, Arribas JR, Assoumou L, Holten AR, Poissy J, Terzić V, Mazzaferri F, Baño JR, Eustace J, Hites M, Joannidis M, Paiva JA, Reuter J, Püntmann I, Patrick-Brown TDJH, Westerheim E, Nezvalova-Henriksen K, Beniguel L, Dahl TB, Bouscambert M, Halanova M, Péterfi Z, Tsiodras S, Rezek M, Briel M et al. (2023)
Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial
Crit Care, 27 (1), 9
DOI 10.1186/s13054-022-04205-8, PubMed 36627655

Leiva RA, Bergersen BM, Finbråten AK, Sandvei PK, Simonsen Ø, Rosseland CM, Hagen K, Young L, Roberts RS, Mikkelsen Y, Singh R, Lagging M, Dalgard O (2022)
High real-world effectiveness of 12-week elbasvir/grazoprevir without resistance testing in the treatment of patients with HCV genotype 1a infection in Norway
Scand J Gastroenterol, 58 (3), 264-268
DOI 10.1080/00365521.2022.2118555, PubMed 36063075

Grebely J, Dore GJ, Altice FL, Conway B, Litwin AH, Norton BL, Dalgard O, Gane EJ, Shibolet O, Nahass R, Luetkemeyer AF, Peng CY, Iser D, Gendrano IN, Kelly MM, Hwang P, Asante-Appiah E, Haber BA, Barr E, Robertson MN, Platt H (2022)
Reinfection and Risk Behaviors After Treatment of Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy : A Cohort Study
Ann Intern Med, 175 (9), 1221-1229
DOI 10.7326/M21-4119, PubMed 35939812

Dalgard O, Litwin AH, Shibolet O, Grebely J, Nahass R, Altice FL, Conway B, Gane EJ, Luetkemeyer AF, Peng CY, Iser D, Gendrano IN, Kelly MM, Haber BA, Platt H, Puenpatom A, CO-STAR Investigators (2022)
Health-related quality of life in people receiving opioid agonist treatment and treatment for hepatitis C virus infection
J Addict Dis, 41 (3), 213-224
DOI 10.1080/10550887.2022.2088978, PubMed 35920743

Midgard H, Bjørnestad R, Egeland M, Dahl E, Finbråten AK, Kielland KB, Blindheim M, Dalgard O (2022)
Peer support in small towns: A decentralized mobile Hepatitis C virus clinic for people who inject drugs
Liver Int, 42 (6), 1268-1277
DOI 10.1111/liv.15266, PubMed 35362660

Chalabianloo F, Høiseth G, Vold JH, Johansson KA, Kringen MK, Dalgard O, Ohldieck C, Druckrey-Fiskaaen KT, Aas C, Løberg EM, Bramness JG, Fadnes LT (2022)
Impact of liver fibrosis and clinical characteristics on dose-adjusted serum methadone concentrations
J Addict Dis, 41 (1), 53-63
DOI 10.1080/10550887.2022.2057140, PubMed 35356868

Busschots D, Bielen R, Koc ÖM, Heyens L, Verrando R, de Galocsy C, Van Steenkiste C, Nevens F, Midgard H, Dalgard O, Robaeys G (2021)
Hepatitis C reinfection in former and active injecting drug users in Belgium
Harm Reduct J, 18 (1), 102
DOI 10.1186/s12954-021-00552-x, PubMed 34641896

Barratt-Due A, Olsen IC, Nezvalova-Henriksen K, Kåsine T, Lund-Johansen F, Hoel H, Holten AR, Tveita A, Mathiessen A, Haugli M, Eiken R, Kildal AB, Berg Å, Johannessen A, Heggelund L, Dahl TB, Skåra KH, Mielnik P, Le LAK, Thoresen L, Ernst G, Hoff DAL, Skudal H, Kittang BR, Olsen RB et al. (2021)
Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19 : A Randomized Trial
Ann Intern Med, 174 (9), 1261-1269
DOI 10.7326/M21-0653, PubMed 34251903

Gahrton C, Håkansson A, Kåberg M, Jerkeman A, Häbel H, Dalgard O, Duberg AS, Aleman S (2021)
Mortality among amphetamine users with hepatitis C virus infection: A nationwide study
PLoS One, 16 (6), e0253710
DOI 10.1371/journal.pone.0253710, PubMed 34166475

Duffell E, Cortez-Pinto H, Simonova M, Dalgard O, Dahl EH, de Martel C, Mozalevskis A, Buti M, Pavlova S, Hadzhilova T, Simões C, Katzarov K, Mardh O (2021)
Estimating the attributable fraction of cirrhosis and hepatocellular carcinoma due to hepatitis B and C
J Viral Hepat, 28 (8), 1177-1189
DOI 10.1111/jvh.13545, PubMed 34003542

Fadnes LT, Aas CF, Vold JH, Leiva RA, Ohldieck C, Chalabianloo F, Skurtveit S, Lygren OJ, Dalgård O, Vickerman P, Midgard H, Løberg EM, Johansson KA, INTRO-HCV Study Group (2021)
Integrated treatment of hepatitis C virus infection among people who inject drugs: A multicenter randomized controlled trial (INTRO-HCV)
PLoS Med, 18 (6), e1003653
DOI 10.1371/journal.pmed.1003653, PubMed 34061883

Cunningham EB, Hajarizadeh B, Amin J, Hellard M, Bruneau J, Feld JJ, Cooper C, Powis J, Litwin AH, Marks P, Dalgard O, Conway B, Moriggia A, Stedman C, Read P, Bruggmann P, Lacombe K, Dunlop A, Applegate TL, Matthews GV, Fraser C, Dore GJ, Grebely J (2021)
Reinfection Following Successful Direct-acting Antiviral Therapy for Hepatitis C Virus Infection Among People Who Inject Drugs
Clin Infect Dis, 72 (8), 1392-1400
DOI 10.1093/cid/ciaa253, PubMed 32166305

Axfors C, Schmitt AM, Janiaud P, Van't Hooft J, Abd-Elsalam S, Abdo EF, Abella BS, Akram J, Amaravadi RK, Angus DC, Arabi YM, Azhar S, Baden LR, Baker AW, Belkhir L, Benfield T, Berrevoets MAH, Chen CP, Chen TC, Cheng SH, Cheng CY, Chung WS, Cohen YZ, Cowan LN, Dalgard O et al. (2021)
Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials
Nat Commun, 12 (1), 2349
DOI 10.1038/s41467-021-22446-z, PubMed 33859192

Midgard H, Ulstein K, Backe Ø, Foshaug T, Sørli H, Vennesland K, Nilssen D, Dahl EH, Finbråten AK, Wüsthoff L, Dalgard O (2021)
Hepatitis C treatment and reinfection surveillance among people who inject drugs in a low-threshold program in Oslo, Norway
Int J Drug Policy, 96, 103165
DOI 10.1016/j.drugpo.2021.103165, PubMed 33642182

Cunningham EB, Hajarizadeh B, Amin J, Litwin AH, Gane E, Cooper C, Lacombe K, Hellard M, Read P, Powis J, Dalgard O, Bruneau J, Matthews GV, Feld JJ, Dillon JF, Shaw D, Bruggmann P, Conway B, Fraser C, Marks P, Dore GJ, Grebely J, SIMPLIFY and D3FEAT study groups (2020)
Adherence to Once-daily and Twice-daily Direct-acting Antiviral Therapy for Hepatitis C Infection Among People With Recent Injection Drug Use or Current Opioid Agonist Therapy
Clin Infect Dis, 71 (7), e115-e124
DOI 10.1093/cid/ciz1089, PubMed 31677262

Lyngbakken MN, Berdal JE, Eskesen A, Kvale D, Olsen IC, Rueegg CS, Rangberg A, Jonassen CM, Omland T, Røsjø H, Dalgard O (2020)
A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics
Nat Commun, 11 (1), 5284
DOI 10.1038/s41467-020-19056-6, PubMed 33082342

Midgard H, Finbråten AK, Malme KB, Berg-Pedersen RM, Tanum L, Olsen IC, Bjørnestad R, Dalgard O (2020)
Opportunistic treatment of hepatitis C virus infection (OPPORTUNI-C): study protocol for a pragmatic stepped wedge cluster randomized trial of immediate versus outpatient treatment initiation among hospitalized people who inject drugs
Trials, 21 (1), 524
DOI 10.1186/s13063-020-04434-8, PubMed 32539853

Artenie AA, Cunningham EB, Dore GJ, Conway B, Dalgard O, Powis J, Bruggmann P, Hellard M, Cooper C, Read P, Feld JJ, Hajarizadeh B, Amin J, Lacombe K, Stedman C, Litwin AH, Marks P, Matthews GV, Quiene S, Erratt A, Bruneau J, Grebely J (2020)
Patterns of Drug and Alcohol Use and Injection Equipment Sharing Among People With Recent Injecting Drug Use or Receiving Opioid Agonist Treatment During and Following Hepatitis C Virus Treatment With Direct-acting Antiviral Therapies: An International Study
Clin Infect Dis, 70 (11), 2369-2376
DOI 10.1093/cid/ciz633, PubMed 31300820

Hajarizadeh B, Cunningham EB, Valerio H, Martinello M, Law M, Janjua NZ, Midgard H, Dalgard O, Dillon J, Hickman M, Bruneau J, Dore GJ, Grebely J (2019)
Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis
J Hepatol, 72 (4), 643-657
DOI 10.1016/j.jhep.2019.11.012, PubMed 31785345

Safreed-Harmon K, Blach S, Aleman S, Bollerup S, Cooke G, Dalgard O, Dillon JF, Dore GJ, Duberg AS, Grebely J, Boe Kielland K, Midgard H, Porter K, Razavi H, Tyndall M, Weis N, Lazarus JV (2019)
The Consensus Hepatitis C Cascade of Care: Standardized Reporting to Monitor Progress Toward Elimination
Clin Infect Dis, 69 (12), 2218-2227
DOI 10.1093/cid/ciz714, PubMed 31352481

Gahrton C, Westman G, Lindahl K, Öhrn F, Dalgard O, Lidman C, Nilsson LH, Said K, Duberg AS, Aleman S (2019)
Prevalence of Viremic hepatitis C, hepatitis B, and HIV infection, and vaccination status among prisoners in Stockholm County
BMC Infect Dis, 19 (1), 955
DOI 10.1186/s12879-019-4581-3, PubMed 31706284

Fadnes LT, Aas CF, Vold JH, Ohldieck C, Leiva RA, Chalabianloo F, Skurtveit S, Lygren OJ, Dalgård O, Vickerman P, Midgard H, Løberg EM, Johansson KA, INTRO-HCV Study Group (2019)
Integrated treatment of hepatitis C virus infection among people who inject drugs: study protocol for a randomised controlled trial (INTRO-HCV)
BMC Infect Dis, 19 (1), 943
DOI 10.1186/s12879-019-4598-7, PubMed 31703669

Shridhar Gulati R, Wimalanathan T, Norheim Andersen S, Isaksen K, Lagging M, Midgard H, Moghaddam A, Dalgard O (2019)
The relationship between IFNL4 genotype and the rate of fibrosis in hepatitis C patients
Scand J Gastroenterol, 54 (9), 1172-1175
DOI 10.1080/00365521.2019.1643403, PubMed 31479286

Grebely J, Conway B, Cunningham EB, Fraser C, Moriggia A, Gane E, Stedman C, Cooper C, Castro E, Schmid P, Petoumenos K, Hajarizadeh B, Marks P, Erratt A, Dalgard O, Lacombe K, Feld JJ, Bruneau J, Daulouede JP, Powis J, Bruggmann P, Matthews GV, Kronborg I, Shaw D, Dunlop A et al. (2018)
Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy
Int J Drug Policy, 62, 94-103
DOI 10.1016/j.drugpo.2018.10.004, PubMed 30384028

Cunningham EB, Amin J, Feld JJ, Bruneau J, Dalgard O, Powis J, Hellard M, Cooper C, Read P, Conway B, Dunlop AJ, Norton B, Litwin AH, Hajarizadeh B, Thurnheer MC, Dillon JF, Weltman M, Shaw D, Bruggmann P, Gane E, Fraser C, Marks P, Applegate TL, Quiene S, Siriragavan S et al. (2018)
Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study
Int J Drug Policy, 62, 14-23
DOI 10.1016/j.drugpo.2018.08.013, PubMed 30352330

Wisløff T, White R, Dalgard O, Amundsen EJ, Meijerink H, Kløvstad H (2018)
Feasibility of reaching world health organization targets for hepatitis C and the cost-effectiveness of alternative strategies
J Viral Hepat, 25 (9), 1066-1077
DOI 10.1111/jvh.12904, PubMed 29624813

Wisløff T, White R, Dalgard O, Amundsen EJ, Meijerink H, Løvlie AL, Kløvstad H (2018)
Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway
Pharmacoeconomics, 36 (5), 591-601
DOI 10.1007/s40273-017-0604-3, PubMed 29396744

Midgard H, Kielland KB, Dalgard O (2018)
[Elimination of hepatitis C is possible]
Tidsskr Nor Laegeforen, 138 (7)
DOI 10.4045/tidsskr.18.0099, PubMed 29663789

Safreed-Harmon K, Hetherington KL, Aleman S, Alho H, Dalgard O, Frisch T, Gottfredsson M, Weis N, Lazarus JV, Hep-Nordic Study Group (2018)
Policy responses to hepatitis C in the Nordic countries: Gaps and discrepant reporting in the Hep-Nordic study
PLoS One, 13 (1), e0190146
DOI 10.1371/journal.pone.0190146, PubMed 29381697

Fraser H, Martin NK, Brummer-Korvenkontio H, Carrieri P, Dalgard O, Dillon J, Goldberg D, Hutchinson S, Jauffret-Roustide M, Kåberg M, Matser AA, Matičič M, Midgard H, Mravcik V, Øvrehus A, Prins M, Reimer J, Robaeys G, Schulte B, van Santen DK, Zimmermann R, Vickerman P, Hickman M (2018)
Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe
J Hepatol, 68 (3), 402-411
DOI 10.1016/j.jhep.2017.10.010, PubMed 29080808

Grebely J, Dalgard O, Conway B, Cunningham EB, Bruggmann P, Hajarizadeh B, Amin J, Bruneau J, Hellard M, Litwin AH, Marks P, Quiene S, Siriragavan S, Applegate TL, Swan T, Byrne J, Lacalamita M, Dunlop A, Matthews GV, Powis J, Shaw D, Thurnheer MC, Weltman M, Kronborg I, Cooper C et al. (2018)
Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial
Lancet Gastroenterol Hepatol, 3 (3), 153-161
DOI 10.1016/S2468-1253(17)30404-1, PubMed 29310928

Bjøro B, Dalgard O, Midgard H, Verbaan H, Småstuen MC, Rustøen T (2017)
Increased hope following successful treatment for hepatitis C infection
J Adv Nurs, 74 (3), 724-733
DOI 10.1111/jan.13487, PubMed 29082540

Marshall AD, Cunningham EB, Nielsen S, Aghemo A, Alho H, Backmund M, Bruggmann P, Dalgard O, Seguin-Devaux C, Flisiak R, Foster GR, Gheorghe L, Goldberg D, Goulis I, Hickman M, Hoffmann P, Jancorienė L, Jarcuska P, Kåberg M, Kostrikis LG, Makara M, Maimets M, Marinho RT, Matičič M, Norris S et al. (2017)
Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe
Lancet Gastroenterol Hepatol, 3 (2), 125-133
DOI 10.1016/S2468-1253(17)30284-4, PubMed 28986139

Meijerink H, White RA, Løvlie A, de Blasio BF, Dalgard O, Amundsen EJ, Melum E, Kløvstad H (2017)
Modelling the burden of hepatitis C infection among people who inject drugs in Norway, 1973-2030
BMC Infect Dis, 17 (1), 541
DOI 10.1186/s12879-017-2631-2, PubMed 28774261

Dalgard O, Weiland O, Noraberg G, Karlsen L, Heggelund L, Färkkilâ M, Balslev U, Belard E, Øvrehus A, Skalshøi Kjær M, Krarup H, Thorup Røge B, Hallager S, Madsen LG, Lund Laursen A, Lagging M, Weis N (2017)
Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections-A Scandinavian real-life study
PLoS One, 12 (7), e0179764
DOI 10.1371/journal.pone.0179764, PubMed 28704381

Midgard H, Hajarizadeh B, Cunningham EB, Conway B, Backmund M, Bruggmann P, Bruneau J, Bourgeois S, Dunlop A, Foster GR, Hellard M, Robaeys G, Thurnheer MC, Weltman M, Amin J, Marks PS, Quiene S, Dore GJ, Dalgard O, Grebely J, ACTIVATE Study Group (2017)
Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study
Int J Drug Policy, 47, 230-238
DOI 10.1016/j.drugpo.2017.05.040, PubMed 28633998

Grebely J, Dalgard O, Cunningham EB, Hajarizadeh B, Foster GR, Bruggmann P, Conway B, Backmund M, Robaeys G, Swan T, Amin J, Marks PS, Quiene S, Applegate TL, Weltman M, Shaw D, Dunlop A, Hellard M, Bruneau J, Midgard H, Bourgeois S, Staehelin C, Dore GJ, ACTIVATE Study Group (2017)
Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study
Int J Drug Policy, 47, 177-186
DOI 10.1016/j.drugpo.2017.05.020, PubMed 28624134

Cunningham EB, Hajarizadeh B, Dalgard O, Amin J, Hellard M, Foster GR, Bruggmann P, Conway B, Backmund M, Robaeys G, Swan T, Marks PS, Quiene S, Applegate TL, Weltman M, Shaw D, Dunlop A, Bruneau J, Midgard H, Bourgeois S, Thurnheer MC, Dore GJ, Grebely J, ACTIVATE Study Group (2017)
Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study
BMC Infect Dis, 17 (1), 420
DOI 10.1186/s12879-017-2517-3, PubMed 28610605

Lamoury FMJ, Soker A, Martinez D, Hajarizadeh B, Cunningham EB, Cunningham P, Bruggmann P, Foster GR, Dalgard O, Backmund M, Conway B, Robaeys G, Swan T, Cloherty G, Marks P, Grebely J, Dore GJ, Applegate TL (2017)
Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse
J Clin Virol, 92, 32-38
DOI 10.1016/j.jcv.2017.05.007, PubMed 28521211

Midgard H, Bramness JG, Skurtveit S, Haukeland JW, Dalgard O (2016)
Hepatitis C Treatment Uptake among Patients Who Have Received Opioid Substitution Treatment: A Population-Based Study
PLoS One, 11 (11), e0166451
DOI 10.1371/journal.pone.0166451, PubMed 27846264

Dore GJ, Altice F, Litwin AH, Dalgard O, Gane EJ, Shibolet O, Luetkemeyer A, Nahass R, Peng CY, Conway B, Grebely J, Howe AY, Gendrano IN, Chen E, Huang HC, Dutko FJ, Nickle DC, Nguyen BY, Wahl J, Barr E, Robertson MN, Platt HL, C-EDGE CO-STAR Study Group (2016)
Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial
Ann Intern Med, 165 (9), 625-634
DOI 10.7326/M16-0816, PubMed 27537841

Waldenström J, Westin J, Nyström K, Christensen P, Dalgard O, Färkkilä M, Lindahl K, Nilsson S, Norkrans G, Krarup H, Norrgren H, Rauning Buhl M, Stenmark S, Lagging M (2016)
Randomized Trial Evaluating the Impact of Ribavirin Mono-Therapy and Double Dosing on Viral Kinetics, Ribavirin Pharmacokinetics and Anemia in Hepatitis C Virus Genotype 1 Infection
PLoS One, 11 (5), e0155142
DOI 10.1371/journal.pone.0155142, PubMed 27167219

Midgard H, Bjøro B, Mæland A, Konopski Z, Kileng H, Damås JK, Paulsen J, Heggelund L, Sandvei PK, Ringstad JO, Karlsen LN, Stene-Johansen K, Pettersson JH, Dorenberg DH, Dalgard O (2016)
Hepatitis C reinfection after sustained virological response
J Hepatol, 64 (5), 1020-1026
DOI 10.1016/j.jhep.2016.01.001, PubMed 26780289

Isaksen K, Aabakken L, Grimstad T, Karlsen L, Sandvei PK, Dalgard O (2015)
Hepatitis C treatment at three Norwegian hospitals 2000-2011
Tidsskr Nor Laegeforen, 135 (22), 2052-8
DOI 10.4045/tidsskr.14.1478, PubMed 26627293

Grebely J, Robaeys G, Bruggmann P, Aghemo A, Backmund M, Bruneau J, Byrne J, Dalgard O, Feld JJ, Hellard M, Hickman M, Kautz A, Litwin A, Lloyd AR, Mauss S, Prins M, Swan T, Schaefer M, Taylor LE, Dore GJ, im Namen vom International Network on Hepatitis care in Substance Users (2015)
Empfehlungen zur Hepatitis Versorgung bei Drogenkonsumierenden
Int J Drug Policy, 111, 101670
DOI 10.1016/j.drugpo.2015.11.010, PubMed 26749563

Grebely J, Robaeys G, Bruggmann P, Aghemo A, Backmund M, Bruneau J, Byrne J, Dalgard O, Feld JJ, Hellard M, Hickman M, Kautz A, Litwin A, Lloyd AR, Mauss S, Prins M, Swan T, Schaefer M, Taylor LE, Dore GJ (2015)
Recommandations pour la prise en charge de l'infection par le virus de l'hépatite C chez les usagers de drogues par injection
Int J Drug Policy, 111, 101669
DOI 10.1016/j.drugpo.2015.11.009, PubMed 26847504

Dore GJ, Conway B, Luo Y, Janczewska E, Knysz B, Liu Y, Streinu-Cercel A, Caruntu FA, Curescu M, Skoien R, Ghesquiere W, Mazur W, Soza A, Fuster F, Greenbloom S, Motoc A, Arama V, Shaw D, Tornai I, Sasadeusz J, Dalgard O, Sullivan D, Liu X, Kapoor M, Campbell A et al. (2015)
Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials
J Hepatol, 64 (1), 19-28
DOI 10.1016/j.jhep.2015.08.015, PubMed 26321288

Dalgard O, Martinot-Peignoux M, Verbaan H, Bjøro K, Ring-Larsen H, Marcellin P (2015)
The Usefulness of Defining Rapid Virological Response by a Very Sensitive Assay (TMA) during Treatment of HCV Genotype 2/3 Infection
PLoS One, 10 (8), e0120866
DOI 10.1371/journal.pone.0120866, PubMed 26317978

Gane E, Kershenobich D, Seguin-Devaux C, Kristian P, Aho I, Dalgard O, Shestakova I, Nymadawa P, Blach S, Acharya S, Anand AC, Andersson MI, Arendt V, Arkkila P, Baatarkhuu O, Barclay K, Ben-Ari Z, Bergin C, Bessone F, Blokhina N, Brunton CR, Choudhuri G, Chulanov V, Cisneros L, Croes EA et al. (2015)
Strategies to manage hepatitis C virus (HCV) infection disease burden - volume 2
J Viral Hepat, 22 Suppl 1, 46-73
DOI 10.1111/jvh.12352, PubMed 25560841

Saraswat V, Norris S, de Knegt RJ, Sanchez Avila JF, Sonderup M, Zuckerman E, Arkkila P, Stedman C, Acharya S, Aho I, Anand AC, Andersson MI, Arendt V, Baatarkhuu O, Barclay K, Ben-Ari Z, Bergin C, Bessone F, Blach S, Blokhina N, Brunton CR, Choudhuri G, Chulanov V, Cisneros L, Croes EA et al. (2015)
Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 2
J Viral Hepat, 22 Suppl 1, 6-25
DOI 10.1111/jvh.12350, PubMed 25560839

Hatzakis A, Chulanov V, Gadano AC, Bergin C, Ben-Ari Z, Mossong J, Schréter I, Baatarkhuu O, Acharya S, Aho I, Anand AC, Andersson MI, Arendt V, Arkkila P, Barclay K, Bessone F, Blach S, Blokhina N, Brunton CR, Choudhuri G, Cisneros L, Croes EA, Dahgwahdorj YA, Dalgard O, Daruich JR et al. (2015)
The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm - volume 2
J Viral Hepat, 22 Suppl 1, 26-45
DOI 10.1111/jvh.12351, PubMed 25560840

Kielland KB, Amundsen EJ, Dalgard O (2014)
HCV treatment uptake in people who have injected drugs - observations in a large cohort that received addiction treatment 1970-1984
Scand J Gastroenterol, 49 (12), 1465-72
DOI 10.3109/00365521.2014.968860, PubMed 25310139

Kielland KB, Delaveris GJ, Rogde S, Eide TJ, Amundsen EJ, Dalgard O (2013)
Liver fibrosis progression at autopsy in injecting drug users infected by hepatitis C: a longitudinal long-term cohort study
J Hepatol, 60 (2), 260-6
DOI 10.1016/j.jhep.2013.09.022, PubMed 24096048

Grady BP, Schinkel J, Thomas XV, Dalgard O (2013)
Hepatitis C virus reinfection following treatment among people who use drugs
Clin Infect Dis, 57 Suppl 2, S105-10
DOI 10.1093/cid/cit301, PubMed 23884057

Robaeys G, Grebely J, Mauss S, Bruggmann P, Moussalli J, De Gottardi A, Swan T, Arain A, Kautz A, Stöver H, Wedemeyer H, Schaefer M, Taylor L, Backmund M, Dalgard O, Prins M, Dore GJ, International Network on Hepatitis in Substance Users (2013)
Recommendations for the management of hepatitis C virus infection among people who inject drugs
Clin Infect Dis, 57 Suppl 2, S129-37
DOI 10.1093/cid/cit302, PubMed 23884061

Lagging M, Rembeck K, Rauning Buhl M, Christensen P, Dalgard O, Färkkilä M, Hellstrand K, Langeland N, Lindh M, Westin J, Norkrans G (2013)
Retreatment with peg-interferon and ribavirin in patients with chronic hepatitis C virus genotype 2 or 3 infection with prior relapse
Scand J Gastroenterol, 48 (7), 839-47
DOI 10.3109/00365521.2013.793389, PubMed 23795661

Kielland KB, Skaug K, Amundsen EJ, Dalgard O (2012)
All-cause and liver-related mortality in hepatitis C infected drug users followed for 33 years: a controlled study
J Hepatol, 58 (1), 31-7
DOI 10.1016/j.jhep.2012.08.024, PubMed 22960427

Eskesen AN, Melum E, Moghaddam A, Bjøro K, Verbaan H, Ring-Larsen H, Dalgard O (2012)
Genetic variants at the ITPA locus protect against ribavirin-induced hemolytic anemia and dose reduction in an HCV G2/G3 cohort
Eur J Gastroenterol Hepatol, 24 (8), 890-6
DOI 10.1097/MEG.0b013e3283546efd, PubMed 22584257

Béziat V, Dalgard O, Asselah T, Halfon P, Bedossa P, Boudifa A, Hervier B, Theodorou I, Martinot M, Debré P, Björkström NK, Malmberg KJ, Marcellin P, Vieillard V (2011)
CMV drives clonal expansion of NKG2C+ NK cells expressing self-specific KIRs in chronic hepatitis patients
Eur J Immunol, 42 (2), 447-57
DOI 10.1002/eji.201141826, PubMed 22105371

Moghaddam A, Melum E, Reinton N, Ring-Larsen H, Verbaan H, Bjøro K, Dalgard O (2011)
IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection
Hepatology, 53 (3), 746-54
DOI 10.1002/hep.24154, PubMed 21374656

Dalgard O (2011)
[New guidelines for investigation and treatment of hepatitis C]
Tidsskr Nor Laegeforen, 131 (1), 15
DOI 10.4045/tidsskr.10.0240, PubMed 21233879

Midgard H, Bang C, Raknerud N, Dalgard O (2010)
Liver fibrosis in hepatitis C patients of Pakistani versus Scandinavian origin
Scand J Gastroenterol, 45 (12), 1503-8
DOI 10.3109/00365521.2010.510571, PubMed 20698740

Dalgard O, Bjoro K, Ring-Larsen H, Verbaan H (2010)
In patients with HCV genotype 2 or 3 infection and RVR 14 weeks treatment is noninferior to 24 weeks. Pooled analysis of two Scandinavian trials
Eur J Gastroenterol Hepatol, 22 (5), 552-6
DOI 10.1097/MEG.0b013e328335b29e, PubMed 20154627

Mangia A, Dalgard O, Minerva N, Verbaan H, Bacca D, Ring-Larsen H, Copetti M, Carretta V, Piazzolla V, Cozzolongo R, Mottola L, Andriulli A (2010)
Ribavirin dosage in patients with HCV genotypes 2 and 3 who completed short therapy with peg-interferon alpha-2b and ribavirin
Aliment Pharmacol Ther, 31 (12), 1346-53
DOI 10.1111/j.1365-2036.2010.04290.x, PubMed 20222909

Dalgard O, Egeland A, Ervik R, Vilimas K, Skaug K, Steen TW (2009)
[Risk factors for hepatitis C among injecting drug users in Oslo]
Tidsskr Nor Laegeforen, 129 (2), 101-4
DOI 10.4045/tidsskr.09.35002, PubMed 19151801

Björnsson E, Verbaan H, Oksanen A, Frydén A, Johansson J, Friberg S, Dalgård O, Kalaitzakis E (2009)
Health-related quality of life in patients with different stages of liver disease induced by hepatitis C
Scand J Gastroenterol, 44 (7), 878-87
DOI 10.1080/00365520902898135, PubMed 19437190

Dalgard O, Bjøro K, Ring-Larsen H, Bjornsson E, Holberg-Petersen M, Skovlund E, Reichard O, Myrvang B, Sundelöf B, Ritland S, Hellum K, Frydén A, Florholmen J, Verbaan H, North-C Group (2008)
Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response
Hepatology, 47 (1), 35-42
DOI 10.1002/hep.21975, PubMed 17975791

Ayuso-Mateos JL, Pereda A, Dunn G, Vazquez-Barquero JL, Casey P, Lehtinen V, Dalgard O, Wilkinson G, Dowrick C (2006)
Predictors of compliance with psychological interventions offered in the community
Psychol Med, 37 (5), 717-25
DOI 10.1017/S0033291706009317, PubMed 17094818

Andriulli A, Dalgard O, Bjøro K, Mangia A (2006)
Short-term treatment duration for HCV-2 and HCV-3 infected patients
Dig Liver Dis, 38 (10), 741-8
DOI 10.1016/j.dld.2006.06.006, PubMed 16916631

Moghaddam A, Reinton N, Dalgard O (2006)
A rapid real-time PCR assay for determination of hepatitis C virus genotypes 1, 2 and 3a
J Viral Hepat, 13 (4), 222-9
DOI 10.1111/j.1365-2893.2005.00678.x, PubMed 16611187

Dalgard O, Mangia A (2006)
Short-term therapy for patients with hepatitis C virus genotype 2 or 3 infection
Drugs, 66 (14), 1807-15
DOI 10.2165/00003495-200666140-00003, PubMed 17040112

Review articles

Day E, Hellard M, Treloar C, Bruneau J, Martin NK, Øvrehus A, Dalgard O, Lloyd A, Dillon J, Hickman M, Byrne J, Litwin A, Maticic M, Bruggmann P, Midgard H, Norton B, Trooskin S, Lazarus JV, Grebely J, International Network on Hepatitis in Substance Users (INHSU) (2018)
Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework
Liver Int, 39 (1), 20-30
DOI 10.1111/liv.13949, PubMed 30157316

Midgard H, Weir A, Palmateer N, Lo Re V, Pineda JA, Macías J, Dalgard O (2016)
HCV epidemiology in high-risk groups and the risk of reinfection
J Hepatol, 65 (1 Suppl), S33-S45
DOI 10.1016/j.jhep.2016.07.012, PubMed 27641987

Cornberg M, Razavi HA, Alberti A, Bernasconi E, Buti M, Cooper C, Dalgard O, Dillion JF, Flisiak R, Forns X, Frankova S, Goldis A, Goulis I, Halota W, Hunyady B, Lagging M, Largen A, Makara M, Manolakopoulos S, Marcellin P, Marinho RT, Pol S, Poynard T, Puoti M, Sagalova O et al. (2011)
A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel
Liver Int, 31 Suppl 2, 30-60
DOI 10.1111/j.1478-3231.2011.02539.x, PubMed 21651702

Sulkowski MS, Cooper C, Hunyady B, Jia J, Ogurtsov P, Peck-Radosavljevic M, Shiffman ML, Yurdaydin C, Dalgard O (2011)
Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C
Nat Rev Gastroenterol Hepatol, 8 (4), 212-23
DOI 10.1038/nrgastro.2011.21, PubMed 21386812

Carvalho-Filho RJ, Dalgard O (2010)
Individualized treatment of chronic hepatitis C with pegylated interferon and ribavirin
Pharmgenomics Pers Med, 3, 1-13
DOI 10.2147/pgpm.s4461, PubMed 23226039

Vik IS, Skaug K, Dalgard O, Steen TW, Hoddevik G (2008)
[Hepatitis C--a health problem also in Norway]
Tidsskr Nor Laegeforen, 128 (5), 563-6
PubMed 18311199